| Literature DB >> 14592525 |
Andrew P Owens1, Alan Nadin, Adam C Talbot, Earl E Clarke, Timothy Harrison, Huw D Lewis, Michael Reilly, Jonathan D J Wrigley, José L Castro.
Abstract
In this paper, we describe the development of a novel series of high affinity, orally bioavailable 3-amino-1,4 benzodiazepine-based gamma-secretase inhibitors for the potential treatment of Alzheimer's disease. We disclose structure-activity relationships based around the 1, 3 and 5 positions of the benzodiazepine core structure.Entities:
Mesh：
Substances：
Year: 2003 PMID： 14592525 DOI： 10.1016/j.bmcl.2003.07.031
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823